Risedronate Sodium Patent Expiration

Risedronate Sodium is Used for prevention and treatment of osteoporosis, including in postmenopausal women, as well as for treating Paget's disease. It was first introduced by Allergan Pharmaceuticals International Ltd in its drug Actonel on Mar 27, 1998. Another drug containing Risedronate Sodium is Atelvia. 12 different companies have introduced drugs containing Risedronate Sodium.


Risedronate Sodium Patents

Given below is the list of patents protecting Risedronate Sodium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Atelvia US7645459 Dosage forms of bisphosphonates Jan 09, 2028 Apil
Atelvia US7645460 Dosage forms of risedronate Jan 09, 2028 Apil
Atelvia US8246989 Dosage forms of bisphosphonates Jan 16, 2026 Apil
Actonel US7192938

(Pediatric)

Method of treatment using bisphosphonic acid Nov 06, 2023

(Expired)

Apil
Actonel US7718634

(Pediatric)

Method of treatment using bisphosphonic acid Nov 06, 2023

(Expired)

Apil
Actonel US7192938 Method of treatment using bisphosphonic acid May 06, 2023

(Expired)

Apil
Actonel US7718634 Method of treatment using bisphosphonic acid May 06, 2023

(Expired)

Apil
Actonel US6465443

(Pediatric)

Method for inhibiting bone resorption Feb 14, 2019

(Expired)

Apil
Actonel US5994329

(Pediatric)

Method for inhibiting bone resorption Jan 17, 2019

(Expired)

Apil
Actonel US6015801

(Pediatric)

Method for inhibiting bone resorption Jan 17, 2019

(Expired)

Apil
Actonel US6432932

(Pediatric)

Method for inhibiting bone resorption Jan 17, 2019

(Expired)

Apil
Actonel US6165513

(Pediatric)

Film-coated tablet for improved upper gastrointestinal tract safety Dec 10, 2018

(Expired)

Apil
Actonel US6465443 Method for inhibiting bone resorption Aug 14, 2018

(Expired)

Apil
Actonel US5994329 Method for inhibiting bone resorption Jul 17, 2018

(Expired)

Apil
Actonel US6015801 Method for inhibiting bone resorption Jul 17, 2018

(Expired)

Apil
Actonel US6432932 Method for inhibiting bone resorption Jul 17, 2018

(Expired)

Apil
Actonel US6165513 Film-coated tablet for improved upper gastrointestinal tract safety Jun 10, 2018

(Expired)

Apil
Actonel US5583122

(Pediatric)

Pharmaceutical compositions containing geminal diphosphonates Jun 10, 2014

(Expired)

Apil
Atelvia US5583122

(Pediatric)

Pharmaceutical compositions containing geminal diphosphonates Jun 10, 2014

(Expired)

Apil
Atelvia US5622721 Dosage forms of risedronate Apr 21, 2014

(Expired)

Apil
Actonel US5583122 Pharmaceutical compositions containing geminal diphosphonates Dec 10, 2013

(Expired)

Apil
Atelvia US5583122 Pharmaceutical compositions containing geminal diphosphonates Dec 10, 2013

(Expired)

Apil



Risedronate Sodium's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Risedronate Sodium Generic API Manufacturers

Several generic applications have been filed for Risedronate Sodium. The first generic version for Risedronate Sodium was by Teva Pharmaceuticals Usa and was approved on Oct 5, 2007. And the latest generic version is by Sun Pharmaceutical Industries Ltd and was approved on Jul 9, 2019.

Given below is the list of companies who have filed for Risedronate Sodium generic, along with the locations of their manufacturing plants worldwide.